Zonisamide for Bipolar Depression: A Randomized, Double Blind, Placebo-Controlled, Adjunctive Trial

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Trials

Background:

• Bipolar depression is a challenging condition with limited treatment options.
• Preliminary studies suggested zonisamide might be effective for bipolar depression.

Purpose of the Study:

• To evaluate the safety and efficacy of adjunctive zonisamide for bipolar depression.
• To conduct the first multicenter, double-blind, randomized, placebo-controlled trial on this topic.

Main Methods:

• 102 patients with bipolar disorder (Type I or II) in a depressive phase were randomized.
• Treatment involved 6 weeks of adjunctive zonisamide or placebo, with MADRS score as the primary outcome.
• Secondary outcomes included YMRS, CGI, Q-LES-Q, response/remission rates, metabolic parameters, and side effects.

Main Results:

• No statistically significant differences in response or remission rates were observed between the zonisamide and placebo groups.
• Adjunctive zonisamide did not show efficacy for primary or secondary outcome measures in bipolar depression.

Conclusions:

• This large, controlled study failed to confirm the efficacy of zonisamide for bipolar depression suggested by earlier open-label studies.
• Zonisamide is not an effective adjunctive treatment for bipolar depression based on these findings.